Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1994 Jun;78(6):446–448. doi: 10.1136/bjo.78.6.446

Evidence for a new role of natriuretic peptides: control of intraocular pressure.

T J Wolfensberger 1, D R Singer 1, T Freegard 1, N D Markandu 1, M G Buckley 1, G A MacGregor 1
PMCID: PMC504820  PMID: 8060926

Abstract

To study the possible physiological role of atrial natriuretic peptide (ANP) in the regulation of intraocular pressure (IOP) the effects of an increase of endogenous ANP within the physiological range induced by the neutral endopeptidase 24.11 (NEP) inhibitor candoxatril were examined. In a single masked placebo controlled trial, seven patients were studied with normal IOP (six male, one female; average age 50 (range 37-62 years). Intraocular pressure in each eye was measured after 2 weeks of placebo, after 4 weeks of candoxatril 200 mg twice daily, and during the first 3 days of placebo washout. With 4 weeks of candoxatril, endogenous plasma ANP levels increased from 4.2 (SEM 1.5) to 6.0 (1.5) pmol/l (p < 0.04) and there was a significant decrease in mean arterial pressure from 119 (4) to 110 (3) mm Hg (p < 0.02; 12 hours after treatment). There was a significant reduction in IOP after 4 weeks' treatment with candoxatril (right eye 2.1 (0.8) mm Hg, p < 0.05 paired t test, left eye 2.8 (0.8) mm Hg, p < 0.02). The mean fall in IOP was 11% (4%) in the right eye and 16% (3%) in the left eye and the fall in IOP was greater the higher the initial IOP. The reduction in IOP with chronic NEP inhibition was positively correlated with the increase in ANP levels but not with changes in blood pressure. These findings suggest that ANP may play a physiological role in the regulation of IOP. As the fall in IOP was greater in subjects with higher initial IOP, NEP inhibitors may be of therapeutic value in the management of glaucoma.

Full text

PDF
446

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. V., Donckier J., Payne N. N., Beacham J., Slater J. D., Bloom S. R. Atrial natriuretic peptide: evidence of action as a natriuretic hormone at physiological plasma concentrations in man. Clin Sci (Lond) 1987 Mar;72(3):305–312. doi: 10.1042/cs0720305. [DOI] [PubMed] [Google Scholar]
  2. Bianchi C., Anand-Srivastava M. B., De Léan A., Gutkowska J., Forthomme D., Genest J., Cantin M. Localization and characterization of specific receptors for atrial natriuretic factor in the ciliary processes of the eye. Curr Eye Res. 1986 Apr;5(4):283–293. doi: 10.3109/02713688609020054. [DOI] [PubMed] [Google Scholar]
  3. Diestelhorst M., Krieglstein G. K. The intraocular pressure response of human atrial natriuretic factor in glaucoma. Int Ophthalmol. 1989 Jan;13(1-2):99–101. doi: 10.1007/BF02028647. [DOI] [PubMed] [Google Scholar]
  4. Erdös E. G., Skidgel R. A. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. 1989 Feb;3(2):145–151. [PubMed] [Google Scholar]
  5. García de Lacoba M., Fernández-Durango R., Triviño A., Ramírez J. M., Ramírez A. I., Salazar J. J., Fernández-Cruz A., Gutkowska J. Existencia del péptido atrial natriurético en coroides, retina y cuerpo ciliar de conejo. Rev Esp Fisiol. 1991 Jun;47(2):91–96. [PubMed] [Google Scholar]
  6. George C. F., Lewis P. J., Petrie A. Clinical experience with use of ultrasound sphygmomanometer. Br Heart J. 1975 Aug;37(8):804–807. doi: 10.1136/hrt.37.8.804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kahn H. A., Leibowitz H. M., Ganley J. P., Kini M. M., Colton T., Nickerson R. S., Dawber T. R. The Framingham Eye Study. II. Association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. Am J Epidemiol. 1977 Jul;106(1):33–41. doi: 10.1093/oxfordjournals.aje.a112429. [DOI] [PubMed] [Google Scholar]
  8. Korenfeld M. S., Becker B. Atrial natriuretic peptides. Effects on intraocular pressure, cGMP, and aqueous flow. Invest Ophthalmol Vis Sci. 1989 Nov;30(11):2385–2392. [PubMed] [Google Scholar]
  9. Minckler D. S., Baerveldt G., Heuer D. K., Quillen-Thomas B., Walonker A. F., Weiner J. Clinical evaluation of the Oculab Tono-Pen. Am J Ophthalmol. 1987 Aug 15;104(2):168–173. doi: 10.1016/0002-9394(87)90010-9. [DOI] [PubMed] [Google Scholar]
  10. Mittag T. W., Tormay A., Ortega M., Severin C. Atrial natriuretic peptide (ANP), guanylate cyclase, and intraocular pressure in the rabbit eye. Curr Eye Res. 1987 Oct;6(10):1189–1196. doi: 10.3109/02713688709025228. [DOI] [PubMed] [Google Scholar]
  11. Nathanson J. A. Atriopeptin-activated guanylate cyclase in the anterior segment. Identification, localization, and effects of atriopeptins on IOP. Invest Ophthalmol Vis Sci. 1987 Aug;28(8):1357–1364. [PubMed] [Google Scholar]
  12. Peczon J. D., Grant W. M. Diuretic drugs in glaucoma. Am J Ophthalmol. 1968 Oct;66(4):680–683. doi: 10.1016/0002-9394(68)91289-0. [DOI] [PubMed] [Google Scholar]
  13. Richards A. M., Espiner E. A., Ikram H., Yandle T. G. Atrial natriuretic factor in hypertension: bioactivity at normal plasma levels. Hypertension. 1989 Sep;14(3):261–268. doi: 10.1161/01.hyp.14.3.261. [DOI] [PubMed] [Google Scholar]
  14. Richards M., Espiner E., Frampton C., Ikram H., Yandle T., Sopwith M., Cussans N. Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension. 1990 Sep;16(3):269–276. doi: 10.1161/01.hyp.16.3.269. [DOI] [PubMed] [Google Scholar]
  15. Sagnella G. A., MacGregor G. A. Atrial natriuretic peptides. Q J Med. 1990 Oct;77(282):1001–1007. doi: 10.1093/qjmed/77.1.1001. [DOI] [PubMed] [Google Scholar]
  16. Sagnella G. A., Markandu N. D., Shore A. C., MacGregor G. A. Effects of changes in dietary sodium intake and saline infusion on immunoreactive atrial natriuretic peptide in human plasma. Lancet. 1985 Nov 30;2(8466):1208–1211. doi: 10.1016/s0140-6736(85)90741-x. [DOI] [PubMed] [Google Scholar]
  17. Samuelsson-Almén M., Nilsson S. F., Mäepea O., Bill A. Effects of atrial natriuretic factor (ANF) on intraocular pressure and aqueous humor flow in the cynomolgus monkey. Exp Eye Res. 1991 Aug;53(2):253–260. doi: 10.1016/0014-4835(91)90081-o. [DOI] [PubMed] [Google Scholar]
  18. Shiose Y., Kawase Y. A new approach to stratified normal intraocular pressure in a general population. Am J Ophthalmol. 1986 Jun 15;101(6):714–721. doi: 10.1016/0002-9394(86)90776-2. [DOI] [PubMed] [Google Scholar]
  19. Singer D. R., Markandu N. D., Buckley M. G., Miller M. A., Sagnella G. A., MacGregor G. A. Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension. Hypertension. 1991 Dec;18(6):798–804. doi: 10.1161/01.hyp.18.6.798. [DOI] [PubMed] [Google Scholar]
  20. Stone R. A., Glembotski C. C. Immunoactive atrial natriuretic peptide in the rat eye: molecular forms in anterior uvea and retina. Biochem Biophys Res Commun. 1986 Jan 29;134(2):1022–1028. doi: 10.1016/s0006-291x(86)80523-x. [DOI] [PubMed] [Google Scholar]
  21. Sugrue M. F., Viader M. P. Synthetic atrial natriuretic factor lowers rabbit intraocular pressure. Eur J Pharmacol. 1986 Nov 4;130(3):349–350. doi: 10.1016/0014-2999(86)90292-x. [DOI] [PubMed] [Google Scholar]
  22. de Bold A. J. Atrial natriuretic factor: a hormone produced by the heart. Science. 1985 Nov 15;230(4727):767–770. doi: 10.1126/science.2932797. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES